Phibro Animal Health's acquisition strengthens its ddPCR offering and expands into new markets.
1 report, 1 independent
Updated Sep 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Phibro Animal Health's acquisition strengthens its ddPCR offering and expands into new markets.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bio-Rad Laboratories
American life science research firm
- Strategic acquisitions and product launches are driving growth for Bio-Rad Laboratories in the life science ddPCR and clinical diagnostics markets.
- Bio-Rad Laboratories is applying digital PCR technology through current partnerships, including Biodesix, Gencove, Insight Molecular, and Stilla Technologies.
-
Phibro
international physical commodities trading firm
Coverage
Newest first; wire copies grouped- ZacksIs it Apt to Hold Bio-Rad Stock in Your Portfolio Now? Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR